Related Experiment Video
Updated: May 13, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled
R Bouamar1, N Shuker, D A Hesselink
1Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands.
Abstract:
Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the concentration-effect relationship for Tac is poorly defined. This study investigated whether Tac concentrations are associated with acute rejection in kidney transplant recipients. Data from three large trials were pooled. We used univariate and multivariate analysis to investigate the relationship between biopsy-proven acute rejection (BPAR) and Tac predose concentration at five time points (day 3, 10 and 14, and month 1 and 6 after transplantation). A total of 136/1304 patients experienced BPAR, giving an overall incidence of 10.4%. We did not find any significant correlations between Tac predose concentrations and the incidence of BPAR at the different time points. In the multivariate analysis, only delayed graft function (DGF) and the use of induction therapy were independently correlated with BPAR, with an odds ratio of 2.7 [95% CI: 1.8-4.0; p < 0.001] for DGF and 0.66 [95% CI: 0.44-0.99; p = 0.049] for induction therapy. The other variables, including the Tac predose concentrations, were not statistically significantly associated with BPAR. We did not find an association between the Tac predose concentrations measured at five time points after kidney transplantation and the incidence of acute rejection occurring thereafter. Based on this study it is not possible to define the optimal target concentrations for Tac.
Insights
Therapeutic drug monitoring of tacrolimus (Tac) is common, but its effectiveness in preventing kidney transplant rejection is unclear. This study found no significant association between Tac concentrations and acute rejection, suggesting current targets may need reevaluation.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is standard practice in kidney transplantation.
- The precise concentration-effect relationship for Tac, particularly concerning acute rejection, remains poorly defined.
Purpose of the Study:
- To investigate the association between tacrolimus predose concentrations and biopsy-proven acute rejection (BPAR) in kidney transplant recipients.
- To determine if current TDM targets for tacrolimus are associated with reduced BPAR incidence.
Main Methods:
- Pooled data from three large clinical trials involving kidney transplant recipients.
- Univariate and multivariate analyses were performed to assess the relationship between Tac predose concentrations and BPAR.
- Tac concentrations were measured at five key time points post-transplantation (days 3, 10, 14, and months 1, 6).
Main Results:
- The overall incidence of BPAR was 10.4% (136/1304 patients).
- No significant correlation was found between tacrolimus predose concentrations and BPAR at any of the assessed time points.
- Delayed graft function and induction therapy were independently associated with BPAR, but tacrolimus levels were not.
Conclusions:
- Tacrolimus predose concentrations measured at five time points after kidney transplantation were not associated with the incidence of acute rejection.
- This study could not establish optimal target concentrations for tacrolimus to prevent BPAR.
- Factors other than tacrolimus levels, such as delayed graft function and induction therapy, appear more critical in predicting acute rejection.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
